Company news
Gyre Therapeutics, Inc. (NASDAQ:GYRE) news
Gyre Therapeutics, Inc. news releases on 6ix. Latest, Sep 3, 2026: Gyre Therapeutics to Participate in Upcoming September Investor Conferences
Press releases & updates
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
September 3, 2026
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
August 7, 2026
Gyre Therapeutics Appoints Three New Members to its Board of Directors
July 16, 2026
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
May 12, 2026
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
May 7, 2026
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S. and China-based Fully Integrated Biopharmaceutical Company
May 5, 2026
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
May 4, 2026
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
March 16, 2026
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 11, 2026
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
March 1, 2026
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
January 4, 2026
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
November 6, 2025
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
October 14, 2025
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
October 13, 2025
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
August 21, 2025
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
August 10, 2025
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
June 9, 2025
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 28, 2025
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
May 21, 2025
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
May 21, 2025
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
May 21, 2025
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
March 30, 2025
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
March 26, 2025
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 16, 2025
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
January 5, 2025
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
November 12, 2024
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
October 21, 2024
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
September 30, 2024
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
August 12, 2024
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
August 8, 2024
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
August 7, 2024
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
July 1, 2024
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
June 17, 2024
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
May 29, 2024
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
May 27, 2024
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 25, 2024
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
March 20, 2024
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
November 12, 2023
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
October 29, 2023
Catalyst Biosciences Provides Corporate Update
February 27, 2023
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
December 26, 2022
Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share
August 31, 2022
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
August 24, 2022
Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation
August 18, 2022
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
August 14, 2022
Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board
August 9, 2022